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The in vitro use of neurons that are differentiated from human induced pluripotent stem
cells (hiPSC-neurons) is expected to improve the prediction accuracy of preclinical
tests for both screening and safety assessments in drug development. To achieve
this goal, hiPSC neurons are required to differentiate into functional neurons that form
excitatory networks and stably express N-methyl-D-aspartate receptors (NMDARs).
Recent studies have identified some astrocyte-derived factors that are important for the
functional maturation of neurons. We therefore examined the effects of the astrocyte-
derived factor glypican 6 (GPC6) on hiPSC-neurons. When we pharmacologically
examined which receptor subtypes mediate L-glutamate (L-Glu)-induced changes in
the intracellular Ca2+ concentrations in hiPSC neurons using fura-2 Ca2+ imaging,
NMDAR-mediated responses were not detected through 7 days in vitro (DIV). These
cells were also not vulnerable to excitotoxicity at 7 DIV. However, a 5-days treatment with
GPC6 from 3 DIV induced an NMDAR-mediated Ca2+ increase in hiPSC-neurons and
increased the level of NMDARs on the cell surface. We also found that GPC6-treated
hiPSC-neurons became responsive to excitotoxicity. These results suggest that GPC6
increases the level of functional NMDARs in hiPSC-neurons. Glial factors may play a key
role in accelerating the functional maturation of hiPSC neurons for drug-development
applications.
Keywords: human induced pluripotent stem cell, neuron, glypican 6, L-glutamate, N-methyl-D-aspartate receptor,
membrane localization, excitotoxicity
INTRODUCTION
Cellular reprogramming, in which terminally differentiated somatic cells are converted into
pluripotent stem cells (induced pluripotent stem cells, i.e., hiPSCs) (Takahashi et al., 2007) is
not only clinically relevant but also useful in drug development because these cells allow for
the homogeneous derivation of mature human cell types in large quantities without the ethical
issues associated with embryonic stem cells. In particular, the in vitro use of neurons differentiated
from hiPSCs (hiPSC-neurons) at the preclinical drug development stage, including assessing
pharmacological safety and searching therapeutic agents, is expected to improve the prediction
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accuracy of the effects of new candidate compounds in humans.
To this end, it is required that hiPSC-neurons differentiate to
functional neurons that form excitatory networks and stably
express N-methyl-D-aspartate receptors (NMDARs). NMDARs
have been implicated as mediators of excitotoxicity (Ferreira
et al., 1996; Stout et al., 1998) and increased attention has
been placed on the possibility of being the therapeutic target of
psychiatric disorders such as schizophrenia (Field et al., 2011).
Huge numbers of astrocytes are generated just prior to the
postnatal wave of synaptogenesis, and astrocyte-derived factors
play important roles in the functional differentiation of neurons
in the developing brain (Wang and Bordey, 2008). Indeed,
recent reports have identified some astrocyte-derived factors that
are important for synaptic maturation (Christopherson et al.,
2005; Allen et al., 2012). Allen et al. (2012) demonstrated that
glypicans (GPCs) 4 and 6 induce functional synaptogenesis in
retinal ganglion cells (RGCs). GPCs 4 and 6 are members of the
6 glycosylphosphatidylinositol (GPI)-anchored heparan sulfate
proteoglycan (HSPG) family, and GPC6 is most homologous
to GPC4 (Veugelers et al., 1999). In the present study, we
examined the effects of GPC6, which is a commercially available
GPC, on hiPSC-neurons. We found that a 5-days treatment
with GPC6 from 3 days in vitro (DIV) increased the level of
functional NMDAR expression on the cell surface. We also
found that GPC6-treated hiPSC-neurons became vulnerable to
excitotoxicity, which is a critical contributor to neuronal injury
in several acute and chronic neurodegenerative disorders (Kritis
et al., 2015). Glial factors may therefore play a key role in
accelerating the functional maturation of hiPSC neurons for
drug-development applications.
MATERIALS AND METHODS
hiPSC-Derived Neuron Culture
Commercially available hiPSC-neurons were used in this study
[iCell Neuron: Cellular Dynamics International (CDI), Madison,
WI, USA] and were cultured according to the manufacturer’s
instructions. The cells were plated in 8-well glass chambers
(155409JP, Nunc, Waltham, MA, USA), 3.5-cm culture dishes,
or 96-well plastic plates, which were pre-coated with poly-D-
lysine (50 µg/ml for 24 h, P6407, Sigma, Darmstadt, Land
Hessen, Germany) followed by a top coating with laminin
(5 µg/ml for 2 h, L2020, Sigma, Darmstadt, Land Hessen,
Germany), at a density of 75,000 cells/cm2 and cultured in iCell
Neuron-maintenance medium (CDI). The medium was changed
24 h after plating and after every 3 days. The reproducibility
of all experimental data was confirmed by three independent
experiments using iCell Neurons with different lot numbers
(#139991, #1361234, #1360614). The all experiments using
hiPSC-neurons were approved by the Research Ethics Committee
of National Institute of Health Sciences (NIHS) in accordance
with the Declaration of Helsinki.
Immunocytochemistry
After fixation with 4% paraformaldehyde (PFA) at room
temperature for 30 min, hiPSC-neurons were permeabilized
with 0.1% (vol/vol) Triton X-100 for 5 min, followed by
treatment with blocking solution (5% [vol/vol] goat serum and
1% [wt/vol] BSA in PBS) for 60 min. After blocking, the cells
were incubated with primary antibody (mouse monoclonal anti-
β3 tubulin antibody [1:500] [MMS-435P, Covance, Princeton,
NJ, USA], chicken polyclonal anti-GFAP antibody [1:400]
[ab4674, Abcam, Cambridge, UK], rabbit polyclonal anti-Nestin
antibody [1:200, AB5922, Millipore, Land Hessen, Germany],
or chicken polyclonal anti-MAP2 antibody [1:5000, AB5392,
Abcam, Cambridge, UK]) in blocking solution at 4◦C for
24 h. After washing, the cells were incubated with solution
containing Alexa Fluor 488-conjugated secondary antibody
(1:500) (Invitrogen, Waltham, MA, USA) and Hoechst 33342
(1:200) (34607951, Dojindo, Kumamoto, Japan) at room
temperature for 3 h. Cultured rat hippocampal neurons were
counted in fluorescence images obtained and analyzed on
a Nikon A1 confocal microscope system (Nikon, Tokyo,
Japan).
GPC6 Treatment
A stock solution of GPC6 (R&D systems, Minneapolis, MN,
USA) (1.55 µM in PBS) was diluted to 10 nM with culture
medium at the time of use. hiPSC-neurons were treated with
GPC6 for 5 days from 3 DIV.
Ca2+ Imaging
hiPSC-neurons or rat hippocampal neurons cultured on eight
well-glass chambers were used for Ca2+ imaging. Changes in
intracellular Ca2+ concentrations ([Ca2+]i) in single cells were
measured using fura-2 as described previously (Koizumi and
Inoue, 1997), with minor modifications. Briefly, the culture
medium was replaced with balanced salt solution (BSS) with
the following composition (mM): NaCl 150, KCl 5.0, CaCl2 1.8,
MgCl2 1.2, N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic
acid (HEPES) 25, and D-glucose 10 (pH = 7.4). The cells were
loaded with 10 µM fura-2 acetoxymethylester (fura-2 AM)
(Dojindo Molecular Technology, Inc., Kumamoto, Japan) in
BSS at room temperature for 45 min and washed with BSS.
The glass chamber was mounted on an inverted epifluorescence
microscope (TE-2000-U, Nikon, Tokyo, Japan). Data were
acquired and processed using Aquacosmos (Hamamatsu
Photonics, Hamamatsu, Japan). Fluorescence images were
obtained via alternate excitation at 340 and 380 nm, and
emission signals were collected at 510 nm from all cells in the
field of view using a charge-coupled device camera (ORCA-R2,
Hamamatsu Photonics, Hamamatsu, Japan) coupled to an image
intensifier (GaAsP, C8600, Hamamatsu Photonics, Hamamatsu,
Japan). Digitized signals were stored and analyzed using the
built-in programs. L-Glu (100 µM in BSS) was applied via
2 min-superfusion at a speed of 1.5 ml/min. D-(-)-2-amino-5-
phosphonopentanoic acid (AP5) (100 µM in BSS) or a mixture
of AP5 and 6,7-dinitroquinoxaline-2,3-dione (DNQX) (100 µM
each in BSS) was applied 1 min before and during L-Glu
application. Ca2+ increases are represented as 5-min area under
the curve (AUC) for ratios of the fluorescence intensities of 340
and 380 nm from the starting point of the response.
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Cell-Surface Biotinylation Assay
Cell-surface proteins were biotinylated using the Pierce Cell
Surface Protein Isolation kit (89881, Thermo Scientific, Waltham,
MA, USA) according to the manufacturer’s instructions. Twelve
3.5-cm culture dishes of cells were used for each group.
The cells were washed with PBS and incubated with EZ-
LINK Sulfo-NHS-SS-biotin at 4◦C for 45 min, followed
by the addition of a quenching solution. The cells were
then lysed with lysis buffer containing 1% (vol/vol) protease
inhibitor cocktail set 1 (539131, Calbiochem, Darmstadt,
Land Hessen, Germany). A portion of the cell lysate was
saved for Western blotting (e.g., total protein fraction). The
remaining cell lysate was applied to the included NeutrAvidin
agarose gel. The flow-through was saved for Western blotting
(e.g., intracellular protein fraction). The total proteins and
intracellular proteins were mixed with 6× sodium dodecyl
sulfate (SDS) sample buffer [6% (wt/vol) SDS, 30% (vol/vol)
sucrose, 0.75% (wt/vol) Bromphenol Blue (BPB), 300 mM
dithiothreitol (DTT) in 375 mM Tris-HCl, pH 6.8]. The
biotinylated proteins were eluted with 1× SDS sample buffer
[1% (wt/vol) SDS, 10% (vol/vol) glycerol, 0.125% (wt/vol)
BPB, 50 mM DTT in 62.5 mM Tris-HCl, pH 6.8] (e.g.,
membrane protein fraction). Each fraction was then loaded
onto a 7.5% polyacrylamide gel, electrophoresed, and transferred
to polyvinyl difluoride (PVDF) membranes. The membranes
were incubated overnight with 4% (wt/vol) BlockAce (DS
Pharma Biomedical, Osaka, Japan) blocking solution at 4◦C. The
membranes were incubated with primary mouse monoclonal
antibodies (mouse monoclonal anti-GluN1 [1:1000] [556308,
BD Pharmingen, Franklin Lakes, NJ, USA], rabbit polyclonal
anti-β-actin [1:5000] [ab8227, Abcam, Cambridge, UK], rabbit
polyclonal anti-GluA1 [1:1000] [ab31232, Abcam, Cambridge,
UK], or mouse monoclonal anti-Na+K+ ATPase [1:5000]
[ab7671, Abcam, Cambridge, UK]) in Can Get SignalTM solution
1 for 60 min at room temperature, followed by incubation with
horseradish peroxidase (HRP)-conjugated secondary antibodies
(anti-rabbit antibody [1:20,000] [GE healthcare, Little Chalfont,
Buckinghamshire, UK] or anti-mouse antibody [1:20,000] [GE
healthcare, Little Chalfont, Buckinghamshire, UK]) in Can Get
SignalTM solution 2 for 60 min at room temperature. The
signals were detected with an LAS3000 (Fuji Photo Film, Co.,
Ltd, Tokyo, Japan) using SuperSignal West Femto Maximum
Sensitivity Substrate (34095, Thermo Scientific, Waltham,
MA, USA). For the relative quantification of the effects of
GPC6 on the cellular distributions of GluN1 and GluA1, the
signal densities in the total protein fractions, the membrane
protein fractions, and the intracellular protein fractions were
normalized to those of the marker proteins for respective
fractions.
MTT Reduction Assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction activity.
MTT reduction activity was measured as described previously
(Abe and Matsuki, 2000; Takaki et al., 2012). Briefly, hiPSC-
neurons cultured in the presence or absence of GPC6 (10 nM)
were exposed to L-Glu (1, 10 mM) for 24 h. MTT was
added to each well at 0.5 mg/mL and incubated for 4 h
at 37◦C. The culture medium in each well was carefully
removed, and 50 µl of DMSO was added to dissolve the
MTT formazan. The relative amount of reaction product (MTT
formazan) was determined by comparing the absorbance at
570 nm (test wavelength) and 655 nm (reference wavelength)
on an iMarkTM microplate reader (Bio-Rad, Hercules, CA,
USA).
Primary Culture of Rat Hippocampal
Neurons
All animals were treated in accordance with the guidelines
for the Care and Use of Laboratory Animals of the Animal
Research Committee of NIHS and followed the Guide for
the Care and Use of Laboratory Animals. All experimental
protocols were approved by the Animal Research Committee of
NIHS and conformed to the relevant regulatory standards. The
brains of 1-day-old Sprague-Dawley (SD) rats were aseptically
removed, and the hippocampi were dissected. The tissues were
dissociated by trituration and trypsinization. After centrifugation
at 1,500 rpm for 5 min, the cells were suspended in Neurobasal
medium supplemented with 2% B27 and 0.1% antibiotic-
antimitotic agent (NB-B27). The residual tissue aggregates were
removed by filtration through a cell strainer with a pore
size of 40–45 mm. The cells were plated in 8-well glass
chambers (155409JP, Nunc, Waltham, MA, USA) or 96-well
plates pre-coated with poly-L-lysine in the mixed medium of
NB-B27 and astrocyte-conditioned medium (ACM) (1:1). The
medium was changed to NB-B27 supplemented with 5 µM
of cytosine arabinoside (AraC) at 1 day post-plating. One-
third of the medium was changed to fresh NB-B27 each week
and cells were cultured at 37◦C in a humidified atmosphere
containing 5% CO2 until 21 DIV.
Data Analysis and Statistics
All data are presented as the mean ± SEM. Statistical analyses
were performed using Tukey’s test following two-way ANOVA
or Student’s t-test. Differences were considered significant at
p < 0.05. The reproducibility of the data was confirmed by
performing three independent experiments.
Materials
The iCell Neurons, iCell Neuron maintenance medium, and
iCell Neuron medium supplement were purchased from Cellular
Dynamics International (CDI, Madison, WI, USA). Recombinant
human GPC6 was purchased from R&D systems (2845-GP-
050, Minneapolis, MN, USA). Fura-2 AM was purchased from
Dojindo Molecular Technology Inc. (Kumamoto, Japan). The
Pierce Cell Surface Protein Isolation kit (89881), SuperSignal
West Femto Maximum Sensitivity Substrate (34095), maximum
sensitivity substrate, BCA protein assay reagents, NB, and
B27 supplements were purchased from Thermo Scientific
(Waltham, MA, USA). HRP-conjugated anti-mouse and anti-
rabbit antibodies were purchased from GE Healthcare Life
Sciences (Little Chalfont, Buckinghamshire, UK). Anti-mouse,
rabbit, goat, and chicken IgGs conjugated with Alexa Fluors
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FIGURE 1 | The cells used in this study. hiPSC-neurons were immunostained with anti-β3 tubulin (top left), anti-Nestin (top right), or anti-GFAP
(bottom left) antibodies and subsequently subjected to Hoechst staining at 3 DIV. The numbers of total cells and cells that were positive for the respective
differentiation markers in a 300 µm × 300 µm area were counted. The ratios of cells that were positive for respective markers are presented as the % total cells
(bottom right). N = 6. The hiPSC-neuron sample used in study contained mostly β3 tubulin+ neurons.
were purchased from Invitrogen (Waltham, MA, USA). Poly-
D-lysine, laminin, BSA, AraC, SDS, and MTT were purchased
from Sigma (St. Louis, MO, USA). PFA and DNQX were
purchased from Wako (Osaka, Japan). Mouse monoclonal anti-
β3 tubulin was purchased from Covance (Princeton, NJ, USA).
Rabbit polyclonal anti-Nestin was purchased from Millipore
(Land Hessen, Germany). Chicken polyclonal anti-GFAP, rabbit
polyclonal anti-β-actin, mouse monoclonal anti-pan-cadherin,
rabbit polyclonal anti-GluA1, chicken anti-MAP2 antibody and
mouse monoclonal anti-Na+K+ ATPase were purchased from
Abcam (Cambridge, UK). Goat serum was purchased from
Rockland (Pottstown, PA, USA). Hoechst 33342 was purchased
from Dojindo (Kumamoto, Japan). AP5 was purchased from
TOCRIS Bioscience (Bristol, UK). Protease inhibitor cocktail
set 1 (539131) was purchased from Calbiochem (Darmstadt,
Land Hessen, Germany). BlockAce was purchased from DS
Pharma Biomedical (Osaka, Japan). Can Get SignalTM was
purchased from Toyobo (Osaka, Japan). Mouse monoclonal anti-
GluN1 was purchased from BD Pharmingen (Franklin Lakes, NJ,
USA).
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FIGURE 2 | GPC6 increased the L-Glu-induced Ca2+ increase in
hiPSC-neurons. (A) Left panel shows the typical control cells loaded with
fura-2 AM. The 5-min area under the curve (AUC) of the ratio of the
fluorescence intensities of 340 and 380 nm from the start of the response to
L-Glu (100 µM, 2 min) (right panel) was quantified. (B) Typical Ca2+ traces
from control and GPC6-treated cells are presented above. In the
GPC6-treated group (n = 68), the average L-Glu-induced Ca2+ increase of all
cells in the field of view was significantly higher than that of the control group
(n = 53). ∗∗p < 0.01 vs. control group, Student’s t-test.
RESULTS
We first performed immunohistochemical staining to investigate
the constituents of the cells used in this study (Figure 1). We
examined the expression of the neuronal marker β3 tubulin, the
stem-cell marker Nestin, and the radial glia/astrocyte marker
GFAP at 3 DIV. Among all cells, 96.05± 0.76% were β3 tubulin+
neurons, and 3.30± 0.69% cells were Nestin+. Few GFAP+ cells
were observed. These data indicate that the hiPSC-neuron sample
used in this study consisted primarily of neurons.
GPC6 has been reported to induce functional synaptogenesis
in RGCs at 10 nM (Allen et al., 2012). We therefore applied
10 nM of GPC6 to the hiPSC-neurons at 3 DIV, at which point
most neurites are attached to each other. After a 5-day incubation
(8 DIV), L-Glu (100 µM, 2 min)-induced Ca2+ increases in
the hiPSC-neurons were examined using fura-2 Ca2+ imaging.
In this study, L-Glu-induced Ca2+ increases were quantified as
the area under the curve (AUC) over a 5-min period from the
start of the response (Figure 2A). As shown in Figure 2B, the
average L-Glu-induced Ca2+ increase in all cells in the field
FIGURE 3 | GPC6 enhanced the NMDAR-mediated Ca2+ increase in
hiPSC-neurons. Typical traces of the Ca2+ increases in control and
GPC6-treated cells are shown above. In the control group, the average value
of the L-Glu-induced Ca2+ increase was not significantly affected by AP5
(n = 53). AP5+DNQX almost completely suppressed the L-Glu-induced Ca2+
increase. In the GPC6-treated group, AP5 significantly suppressed the
L-Glu-induced Ca2+ increase, and AP5+DNQX almost completely
suppressed the L-Glu-induced Ca2+ increase (n = 68). ∗p < 0.05, ∗∗p < 0.01
vs. AP5(-) group. Tukey’s test following ANOVA.
of view was significantly enhanced in the GPC6-treated group
(127 ± 4.89% of control). Representative Ca2+ traces from
control cells and GPC6-treated cells are shown in Figure 2B (top
panels). We next examined the contributions of NMDARs and
non-NMDARs to the L-Glu-induced Ca2+ increase in hiPSC-
neurons. In this experiment, we first examined the effect of AP5
(100 µM) and then examined the effect of a cocktail of AP5
(100 µM) and DNQX (100 µM) on the L-Glu-induced Ca2+
increase (Figure 3). In the control group, although 36.5 ± 3.69%
of cells responded to AP5 (>10% suppression), the average value
of the L-Glu-induced Ca2+ increase in all cells in the field of
view was not affected by AP5. When DNQX was co-applied with
AP5, the L-Glu-induced Ca2+ increase was completely inhibited,
indicating that the L-Glu-induced Ca2+ increase in the control
group was primarily mediated by non-NMDARs. In the GPC6-
treated group, 88.5 ± 7.13% of cells responded to AP5, and the
average value of L-Glu-induced Ca2+ increase in all cells in the
field of view was significantly suppressed by AP5. When DNQX
was co-applied with AP5, the L-Glu-induced Ca2+ increase was
also completely suppressed. The top panels depict typical Ca2+
traces from control and GPC6-treated cells. These results indicate
that GPC6 enhanced the NMDAR-mediated Ca2+ increase in
hiPSC-neurons. The effects of GPC6 were highly reproducible,
with the averaged ratios of the AP5-responsive cells (>10%
suppression) in the control and GPC6-treated groups across the
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FIGURE 4 | GPC6 increased the surface levels of NMDARs of hiPSC-neurons. (A) The expression of markers for intracellular proteins (β-actin) and membrane
proteins (Na+-K+ ATPase) in respective fractions, and the cellular distribution of GluN1 (NMDARs). GPC6 induced an increase in the surface expression level of
GluN1 and a corresponding decrease in intracellular expression, without little effects on the total level. (B) The cellular distribution of GluA1 (AMPARs). GPC6 also
resulted in a slight increase in the surface expression level of GluA1, but the effect was weaker than that on GluN1. Total and intracellular GluA1 levels showed little
change. The data were mean ± SE of three independent experiments.
three experimental sessions being 26.4 ± 3.05 and 82.8 ± 10.7%,
respectively (three experiments, p= 0.00718).
GPC6 has been reported to increase the surface expression
and clustering of the GluA1 subunit of the α-amino 3-hydroxy
5-methyl-4-isoxazolepropionic acid receptor (AMPAR) (Allen
et al., 2012). We therefore examined the effects of GPC6 on the
cellular distribution of NMDARs in hiPSC-neurons (Figure 4).
In this experiment, we performed a cell-surface biotinylation
experiment and quantified the expression of GluN1, which is an
essential subunit for NMDAR channel activity (Meguro et al.,
1992; Wenthold et al., 2003). As shown by the expression of
β-actin and Na+-K+ ATPase, which marked the intracellular
and membrane fractions, respectively, this protocol successfully
separated membrane and intracellular proteins. GPC6 treatment
resulted in increased surface expression of GluN1 (186.1± 19.6%
of control, three experiments) and a decrease in the intracellular
compartment (68.8 ± 12.7% of control, three experiments),
with little effects on total GluN1 levels (Figure 4A). These data
indicate that GPC6 increased the level of NMDARs on the cell
surface of the hiPSC-neurons. We also examined the cellular
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FIGURE 5 | Effects of GPC6 on the sensitivity of hiPSC-neurons to
L-Glu-induced cytotoxicity. After a 5-days treatment with GPC6, cells were
exposed to L-Glu (1, 10 mM, 24 h), and an MTT reduction assay was
performed. L-Glu did not cause cell damage in the control group. In the
GPC6-treated group (10 nM, 5 days), L-Glu caused a
concentration-dependent decrease in MTT reduction. ∗∗p < 0.01 vs. the
control in each group, Tukey’s test following two-way ANOVA (N = 6).
distribution of GluA1 (Figure 4B). Although GPC6 resulted in
a slight increase in the surface level of GluA1 (120.8 ± 2.850%,
three experiments), the effect was weaker than that on GluN1. In
addition, the intracellular and total levels of GluA1 were largely
unaltered.
We next investigated whether the sensitivity of hiPSC-neurons
to L-Glu-induced cytotoxicity was affected by GPC6 treatment
(Figure 5). Cell viability was measured using the MTT reduction
assay. We first confirmed that cultured rat hippocampal neurons
undergo significant damage following 24-h treatment with L-Glu
at concentrations above 10 µM (Supplementary Figure S1A).
After a 5-day treatment with GPC, hiPSC-neurons at 8 DIV
were similarly exposed to L-Glu for 24 h. Although L-Glu did
not cause cell damage in the control group, 10 mM L-Glu
caused a significant decrease in MTT reduction in the GPC6-
treated group. Although the sensitivity to L-Glu was lower in
hiPSC-neurons than in cultured rat hippocampal neurons, GPC6
treatment nevertheless rendered hiPSC-neurons sensitive to L-
Glu-induced cytotoxicity. The GPC6-induced increase in surface
NMDAR expression may be involved in the increased sensitivity
to L-Glu.
DISCUSSION
Since the successful neuronal differentiation of hiPSCs was
first reported (Takahashi et al., 2007; Dimos et al., 2008),
hiPSC-neurons have been expected to improve the prediction
accuracy of the effects of new candidate compounds in
humans during preclinical drug development, and the extent
of functional maturation determines the application of hiPSC-
neurons. In recent reports, Dage et al. (2014) revealed that
hiPSC-neurons express various ion channels and receptors
through a multitude of methods (patch-clamp, calcium flux,
extracellular recordings, etc.). However, the number of cells
that responded to NMDA was still low at 7 DIV (Dage et al.,
2014). In the present study, we clarified that the astrocyte-
derived GPI-anchored HSPG GPC6 increased the cell-surface
NMDAR expression in hiPSC-neurons, rendering them sensitive
to excitotoxicity.
The Significance of Functional NMDA
Receptor Expression in hiPSC-Neurons
N-methyl-D-aspartate receptors have been implicated as
mediators of excitotoxicity associated with many neurological
disorders, including ischemia, epilepsy, brain trauma, dementia,
and neurodegenerative disorders (Doble, 1999; Kemp and
McKernan, 2002). Larger quantities of Ca2+ ions move through
NMDARs, and excessive Ca2+ increases due to NMDARs
lead to excitotoxicity (Ferreira et al., 1996; Stout et al., 1998).
More recently, increased attention has been placed on indirect
increases in NMDAR function to alleviate psychiatric disorders
such as schizophrenia (Field et al., 2011). Thus, NMDAR
ligands, both inhibitors and potentiators, are expected to
be beneficial in the treatment of several neurological and
psychiatric conditions. However, the therapeutic ratio for
most NMDA antagonists is poor, with significant adverse
effects at clinically effective doses (Gardoni and Di Luca,
2006). Our present findings will help expand the study of the
pharmacology of human NMDARs at the preclinical stage.
In this study, L-Glu-induced damage reached significance
at 10 mM in GPC6-treated hiPSC-neurons. This effective
concentration is higher than that for cultured rat hippocampal
neurons. The L-Glu-induced Ca2+ increase in the GPC6-treated
hiPSC-neurons is much lower than that in the cultured rat
neurons (Figure 3; Supplementary Figure S1B), suggesting
that the expression levels of L-Glu receptors in hiPSC-neurons
are still too low to cause L-Glu cytotoxicity comparable
to rat hippocampal neurons. The specific composition of
NMDAR subunits might also be involved in the insufficient
Ca2+ increase. NMDARs are heterotetramers of two GluN1
subunits and two GluN2 subunits (Cull-Candy et al., 2001).
Because GluN2B-containing NMDARs exhibit slower kinetics
than GluN2A-containing receptors (Williams et al., 1993),
GluN2B-containing NMDARs play a larger role in excitotoxicity
than GluN2A-containing NMDARs (Zhou and Baudry,
2006).
Potential of Glial Factors to Enhance the
Functional Maturation of hiPSC-Neurons
Recent studies have shown that interactions with glial
cells are indispensable for the functional maturation
of newborn neurons (Allen, 2013; Corty and Freeman,
2013; Shigemoto-Mogami et al., 2014). Huge numbers of
astrocytes are generated just prior to the postnatal wave of
synaptogenesis and play important roles in synaptogenesis
in the developing brain (Wang and Bordey, 2008). As such,
some reports have demonstrated that co-culturing with
rodent astrocytes promotes the functional maturation of
hiPSC-neurons (Shcheglovitov et al., 2013; Tang et al., 2013;
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 November 2016 | Volume 10 | Article 259
fncel-10-00259 November 11, 2016 Time: 14:42 # 8
Sato et al. Effects of Glypican 6 on hiPSC-Neurons
Odawara et al., 2014). However, the efficiency of the astrocyte
feeder depends on culture viability. Identifying the factors
responsible for the effects of the astrocyte feeder will allow
the functional differentiation of hiPSC-neurons to be controlled
more easily. GPC6 was originally demonstrated to increase the
surface expression and clustering of AMPARs in RGCs, thereby
promoting synaptogenesis (Allen et al., 2012). However, the
precise pathway by which GPC6 exerts these effects remains
to be elucidated. Allen et al. (2012) also have suggested that
GPCs act via the interaction of HS with AMPARs rather than
through the delivery of the associated morphogens. The HSPG
Syndecan-4 is known to be necessary for the trafficking of
transglutaminase-2 to the cell surface (Scarpellini et al., 2009).
HSPGs might commonly regulate the membrane trafficking
of functional proteins. GPC6 may also suppress NMDA
receptor internalization, thereby leading to increased cell-surface
expression. Unfortunately, spontaneous Ca2+ responses that
reflect functional synaptogenesis were not obtained in this study.
The ratio of astrocytes was almost 0% in our hiPSC-neuron
cultures, which is uncommon in primary cultures of rodent
neurons. The astrocyte cell surface may contain additional key
molecules that further enhance functional maturation.
The Functional Maturation Time of
hiPSC-Neurons
Increasing evidence suggests that the functional maturation of
hiPSC-neurons takes longer than that of rodent neurons. Shi
et al. (2012) reported that a 45–100-days differentiation period
is necessary to successfully record miniature excitatory post-
synaptic currents (mEPSCs) from hiPSC-neurons. Moreover,
hiPSC-derived neurons transplanted into mice brains took
several months to establish functional synapses with the host
circuitry, suggesting that the rate of functional synaptogenesis
is an intrinsic property of hiPSC-neurons (Shi et al., 2012;
Espuny-Camacho et al., 2013). A recent report suggested that
the human-specific duplication of the SLIT-ROBO Rho GTPase
activating protein 2 (SRGAP2) gene extends the phase of
spine development and thereby causes ‘spine neoteny,’ which
allows human cortical neurons to receive a significantly higher
number of synaptic inputs (Charrier et al., 2012). Taken together,
these data suggest that the long time period required for the
functional synaptogenesis of hiPSC-neurons may be related
to species differences. To improve the usability of hiPSC
neurons for drug development, functional synaptogenesis over a
shorter period is needed; however, the protocols for accelerating
neuronal maturation should be chosen carefully. Our present
data highlight the promise of glial factors, and glial factors that
are actually active during brain development may be the first
choice to accelerate the functional maturation of hiPSC-neurons
for drug-development applications.
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